摘要
目的研究滤泡树突状细胞肉瘤(FDCS)的临床病理特点及免疫表型,探讨EB病毒感染与FDCS的关系。方法复习6例FDCS临床病理资料,进行光镜观察、免疫组织化学及EB病毒小RNA(EBER)原位杂交分析。结果 6例患者中,男性5例,女性1例,平均年龄34岁。肿瘤发生于淋巴结3例,脾脏、腹膜后及盆腔各1例;形态学上,1例为炎性假瘤样型,5例为普通型;肿瘤细胞均不同程度表达滤泡树突状细胞抗原,Ki-67肿瘤细胞阳性率为2%~30%。炎性假瘤样型FDCS细胞EBER阳性,而普通型阴性;患者手术治疗后,随访10~132个月,2例分别于手术后10个月、16个月复发,1例术后112个月在其他部位淋巴结出现普通型FDCS。复发或再发者再予手术治疗,辅以化疗,均带瘤生存。结论 FDCS组织形态及免疫表型变异较大,预后差异明显。
Objective To study the clinicopathological features and immunophenotypes of follicular dendritic cell sarcoma（FDCS）,and to investigate the relation between Epstein-Barr virus（EBV） and FDCS. Methods We reviewed the clinicopathological data of 6 patients with FDCS,using microscope observation,immunohistochemical staining and in situ hybridization for EBV encoded nuclear RNA（EBER）. Results Five males and one female were included in this study,with an average age of 34. The tumors were located originally in the lymph nodes in 3 cases and in the spleen,retroperitoneal or pelvic cavity in 1 case,respectively. The inflammatory pseudotumor-like type was found histologically in 1 case and the common type in 5 cases. Immunohistochemically,FDC markers expressed in different levels,and the positive rate of Ki-67 was 2% ～ 30% in the tumor cells. The EBER was positive in the inflammatory pseudotumor-like type FDCS,whereas it was negative in the normal type. All the patients were followed up for 10 to 132 months after tumor resection. Two cases relapsed 10 months and 16 months respectively after the operation. The recurrent sarcoma was found in another lymph node in one case 112 months after the surgery. Nevertheless,this patients survived with the tumor after the sequential successful reoperation and the CHOP-based chemotherapy. Conclusion FDCS varies largely in histomorphology and immunopheotype,and is obviously different in prognosis.
出处
《中国临床新医学》
2017年第2期110-113,共4页
CHINESE JOURNAL OF NEW CLINICAL MEDICINE
基金
国家自然科学基金资助项目(编号:81360355)
广西卫计委科研课题(编号:Z2010237
2013355)
关键词
滤泡树突状细胞肉瘤
临床病理特点
EB病毒
预后
Follicular dendritic cell sarcoma（FDCS）
Clinicopathological features
Epstein-Barr virus
Prognosis
